The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)

Study Name on
ClinicalTrialsRegister.eu (link is external)
Trial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis
Study DrugCeftazidime, Tobramycin, Ciprofloxacin
(This trial will assess whether ten days intravenous ceftazidime with tobramycin is superior to three months oral ciprofloxacin at eradicating P. aeruginosa from the lungs of Cystic Fibrosis patients. Both treatment regimes will be in conjunction with three months nebulised colistin)
Type of Study DrugAnti-infective
Study TitleTrial of Optimal Therapy for Pseudomonas Eradication in Cystic Fibrosis
Study Phase4
Study SponsorUniversity Hospitals Bristol NHS Foundation Trust
Link European Trials Register

https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012575-10/GB

Additional information:
http://www.torpedo-cf.org.uk/

Participating ECFS-CTN sitesLeeds, Birmingham, Nottingham, London
AgeChildren over the age of 28 days
No upper age limitation